HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse

被引:7
作者
Kosiewicz, Michele M. [2 ]
Auci, Dominick L. [3 ]
Fagone, Paolo [1 ]
Mangano, Katia [1 ]
Caponnetto, Salvatore [1 ]
Tucker, Colleen F. [2 ]
Azeem, Nabeel [2 ]
White, Steven K. [3 ]
Frincke, James M. [3 ]
Reading, Christopher L. [3 ]
Nicoletti, Ferdinando [1 ]
机构
[1] Univ Catania, Dept Biomed Sci, Sch Med, I-95124 Catania, Italy
[2] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA
[3] Harbor Biosci, San Diego, CA 92122 USA
关键词
Diabetes; IL-17; Androstene; NOD; Steroid; REGULATORY T-CELLS; SOLUBLE INTERLEUKIN-1 RECEPTOR; COLLAGEN-INDUCED ARTHRITIS; IFN-GAMMA; RHEUMATOID-ARTHRITIS; RODENT MODELS; TH17; CELLS; MICE; DISEASE; MELLITUS;
D O I
10.1016/j.ejphar.2011.02.016
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
5-Androstene-3 beta,7 beta,17 beta-triol (AET) is a naturally occurring anti-inflammatory adrenal steroid that limits acute and chronic inflammation. HE3286 (17 alpha-ethynyl-5-androstene-3 beta,7 beta,17 beta-triol) is a synthetic derivative of AFT with improved pharmaceutical properties and efficacy in some animal models of autoimmunity. Here, daily oral doses of HE3286 led to a suppression of spontaneous autoimmune diabetes in the non-obese diabetic mouse model of type 1 diabetes mellitus when administered either shortly before or after the first incidence of disease onset. Efficacy was associated with reduced insulitis and a suppression of the pathogenic T helper cell type 1 and type 17 phenotypes in peripheral lymphoid organs. These results demonstrate that daily oral treatment with HE3286 administrated relatively late in the destructive autoimmune process led to a suppression of type 1 diabetes mellitus onset and of the pathological inflammatory status, supporting its clinical evaluation in type 1 diabetes mellitus subjects. (C) 2011 Published by Elsevier B.V.
引用
收藏
页码:257 / 262
页数:6
相关论文
共 44 条
[1]   β-Cell Mass and Type 1 Diabetes Going, Going, Gone? [J].
Akirav, Eitan ;
Kushner, Jake A. ;
Herold, Kevan C. .
DIABETES, 2008, 57 (11) :2883-2888
[2]   The NOD mouse: A model of immune dysregulation [J].
Anderson, MS ;
Bluestone, JA .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :447-485
[3]   NOD mice and autoimmunity [J].
Aoki, CA ;
Borchers, AT ;
Ridgway, WM ;
Keen, CL ;
Ansari, AA ;
Gershwin, ME .
AUTOIMMUNITY REVIEWS, 2005, 4 (06) :373-379
[4]  
ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428
[5]   A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse - Androstene hormones as regulators of regulatory T cells [J].
Auci, D. ;
Kaler, L. ;
Subramanian, Sandhya ;
Huang, Yugin ;
Frincke, J. ;
Reading, C. ;
Offner, H. .
AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 :630-640
[6]   Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis [J].
Auci, Dominick L. ;
Mangano, Katia ;
Destiche, Daniel ;
White, Steven K. ;
Huang, Yujin ;
Boyle, David ;
Frincke, James ;
Reading, Christopher L. ;
Nicoletti, Ferdinando .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 25 (04) :625-633
[7]   7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases [J].
Auci, Dominick L. ;
Reading, Christopher L. ;
Frincke, James M. .
AUTOIMMUNITY REVIEWS, 2009, 8 (05) :369-372
[8]   Interplay Between Effector Th17 and Regulatory T Cells [J].
Awasthi, Amit ;
Murugaiyan, Gopal ;
Kuchroo, Vijay K. .
JOURNAL OF CLINICAL IMMUNOLOGY, 2008, 28 (06) :660-670
[9]  
BENDING D, 2009, J CLIN INVEST 0202
[10]   Type 1 diabetes mellitus: Primary, secondary, and tertiary prevention [J].
Bollyky, Jennifer ;
Sanda, Srinath ;
Greenbaum, Carla J. .
MOUNT SINAI JOURNAL OF MEDICINE, 2008, 75 (04) :385-397